SAN FRANCISCO—In a presentation on advances in the treatment of systemic lupus erythematosus (SLE) at the California Rheumatology Alliance 2016 Medical & Scientific Meeting in May, Maria Dall’Era, MD, director of the Lupus Clinic and Rheumatology Clinical Research Center at the University of California, San Francisco, discussed the range of treatments that have been identified…
A recent study documented blood transcriptional profiles in pediatric patients with systemic lupus erythematosus (SLE), finding that plasmablast signatures were the most robust biomarker of SLE disease activity. Researchers were further able to stratify patients into groups on the basis of molecular correlates, which may aid in personalizing SLE treatment and identifying biomarkers that can predict occurrence and frequency of flares…
CHICAGO—A lupus expert recently issued a call for action to improve outcomes of lupus clinical trials, a field that has had so many failed potential therapies that he said it seems to be “cursed.” Richard Furie, MD, chief of rheumatology at Northwell Health in New York, said at the ACR’s 2016 State-of-the-Art Clinical Symposium that…
When I began my tenure as ACR president this past November, I posited that it “takes a village” to grow and succeed in rheumatology’s rapidly changing environment. The ACR village includes volunteers who represent a diverse leadership pipeline reflecting the demographics of our younger members. It also includes the international rheumatology community that accounts for…
I read with interest the Diagnostic View (TR, April), which, according to the authors, represented a case of rhupus, an overlap syndrome of RA and SLE. I challenge this view. My arguments: In the case of erosive RA, typically erosive changes are seen at MTP joints other than MTP1 (e.g., MTP5). In addition, the erosive…
New research investigates the role of autophagy, specifically the cell digestion process called LC3-associated phagocytosis (LAP), in inflammation and the pathology of systemic lupus erythematosus (SLE). Researchers found that defects in this process result in failure to digest dying cells, which increases inflammatory cytokine production and results in SLE-like disease in mice. Further exposure to dying cells accelerated disease development…
A recent study from the U.K. calculated the incidence of comorbidity associated with systemic lupus erythematosus (SLE), specifically looking for cardiovascular disease, stroke, end-stage renal failure, cancer, osteoporosis and infection. Even after adjusting for age, sex and other variables, investigators found that people with SLE have an increased global burden of comorbidity compared with the general population. Additionally, the study found that men with SLE had higher rates of cardiovascular disease, stroke and cancer, while women with SLE had higher rates of infection and osteoporosis. Overall, younger people with SLE had the greatest relative risk compared with controls…
New research has found that the amyloid protein curli triggers immune activation and autoantibody production in lupus-prone and wild-type mice. Stefania Gallucci, MD, says these results provide insight into the mechanisms of bacterial infection that may result in lupus…
A recent case study revealed that an infant from a donor egg developed neonatal lupus erythematosus (NLE) and a congenital heart block, which may have been due to the presence of antibodies to Ro and La in the birth mother—not the genetic mother. The results suggest that a gestational mother with a history of autoimmune disease is sufficient to trigger the pathology of NLE…
LONDON (Reuters)—Britain’s healthcare cost watchdog has finally approved GlaxoSmithKline’s lupus drug Benlysta (belimumab) for limited use, after rejecting it since 2011 on the grounds that it failed to offer good value for money. The National Institute for Health and Care Excellence (NICE) said on Tuesday that the drug would be made available under a managed…